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Abstract
Incidence of Leishmania donovani infection and Visceral Leishmaniasis (VL) was assessed in a prospective study in Indian and
Nepalese high-endemic villages. DAT-seroconversion was used as marker of incident infection in 3 yearly surveys. The study
population was followed up to month 30 to identify incident clinical cases. In a cohort of 9034 DAT-negative individuals
with neither active signs nor history of VL at baseline, 42 VL cases and 375 asymptomatic seroconversions were recorded in
the first year, giving an infection:disease ratio of 8.9 to 1. In the 18 months’ follow-up, 7 extra cases of VL were observed in
the seroconverters group (N = 375), against 14 VL cases among the individuals who had not seroconverted in the first year
(N = 8570) (RR = 11.5(4.5,RR,28.3)). Incident asymptomatic L. donovani infection in VL high-endemic foci in India and Nepal
is nine times more frequent than incident VL disease. About 1 in 50 of these new but latent infections led to VL within the
next 18 months.
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Introduction
In the Indian subcontinent 200 million people are estimated to
be at risk of developing Visceral Leishmaniasis (VL). VL, also
known as kala-azar is a fatal parasitic disease caused by Leishmania
donovani, an intracellular parasite transmitted in the Indian
continent by Phlebotomus argentipes. The reported number of cases
in the region was 100,000 per year in 2005, but the actual figure
may be 5 to 8 times higher [1–3].
However, most of L. donovani infections remain asymptomatic
[4]. Cross-sectional surveys based on serological testing by Direct
Agglutination Test (DAT) [5–9] or ELISA [9] and/or positive
delayed-type hypersensitivity (DTH) reaction to a leishmanin skin
test (LST) [10–12] show high proportions of positive persons who
never reported clinical disease. It is unclear whether these
asymptomatic infected persons are infectious to the sandfly vector,
whether they acquire persistent immunity or develop VL later on.
The proportion of L.donovani infections that result in VL disease is
poorly documented as this requires large prospective epidemio-
logical studies. In Brazil the ratio of incident infection to incident
disease ranged between 6.5:1 and 18.5:1 [13–15], whereas in
Africa ratios ranging from 1:2.4 to 11:1 have been reported [16–
19]. In the only population-based longitudinal study in South-East
Asia published so far Bern et al. found a 4:1 ratio of incident
infection versus disease in Bangladesh [20]. Similar estimates are
not yet available for India and Nepal, two other countries affected
by VL in the Indian subcontinent.
The objective of this study was to examine the relationship
between L. donovani infection and clinical disease, and to estimate
the probability of progressing to clinical VL in recently infected
persons in India and Nepal.
Materials and Methods
a. Ethical issues
A large community intervention study to measure effectiveness of
long-lasting insecticide treated bednets (LN) for prevention of VL in
India and Nepal (KALANET, ClinicalTrials.gov NCT00318721)
provided the opportunity to document incident infection and
disease in Nepal and in India. Consent for the Kalanet study was
sought at three levels: community, household and individual.
Communities were duly informed about the purpose of the trial and
consent was sought from village leaders for inclusion of the cluster in
the trial. Written informed consent was obtained from all
participants or their guardians for those under 18 years old. A
literate witness signed on behalf of illiterate participants who added
their thumbprint to the informed consent form. Ethical clearance
was obtained from the ethical committees of BHU (India), the
BPKIHS (Nepal), the London School of Hygiene and Tropical
Medicine (UK), and the University of Antwerp (Belgium).
b. Study site
The study ran from November 2006 to May 2009 in 26 highly
endemic villages. Selection of those villages has been described
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elsewhere [21,22]. The cluster randomized controlled trial did not
show any significant reduction in incidence of L. donovani infection
or VL disease in the intervention villages compared to controls
[23]. For this reason, the study subjects from both intervention and
control villages were included in the current analysis.
c. Study participants and case definitions
Cross-sectional serosurveys were conducted in November–
December 2006 (M0), 2007 (M12) and 2008 (M24) in the 26
study villages. A blood sample was collected from all consenting
individuals over 2 years old. Clinical follow-up was done through
passive and active case detection up to May 2009, i.e. 6 months
after the last serosurvey.
An incident VL case was defined as a subject with a clinical
episode of VL for whom the first clinical symptoms had started
after the baseline serosurvey (November 2006). From November
2006 to May 2009, all subjects with fever lasting for two weeks or
more were examined by a physician and tested with a rapid
diagnostic test (RDT) for VL (Kalazar DetectTM Rapid Test;
InBios International, Seattle, WA). Most VL cases were managed
free of charge at the reference treatment centers i.e. Kala-azar
Medical Research Center, Muzaffarpur, India (KAMRC) and
B.P. Koirala Institute of Health Sciences, Dharan, Nepal
(BPKIHS) where diagnosis was further confirmed by direct
microscopic examination and/or culture of bone marrow or
spleen tissue aspirate. For those who were diagnosed and treated
outside the two reference centers details on diagnosis and
treatment were collected from the subject or his family, and
double-checked with clinical records.
Direct agglutination test (DAT) was used as a marker of
L.donovani infection. We used a cut-off titre of 1:1600 to define
seropositivity. This cut-off is lower than the one used for VL
diagnosis in clinical suspects (1:3200) because we wanted to
increase the sensitivity to detect L. donovani infection [24,25].
Seroconversion was defined as a titer increase of 2 titres or more
above his/her baseline value, since a difference of one titer is
considered a very common (and accepted) inter-observer discrep-
ancy in routine DAT serology reading [26].
d. Laboratory procedures
In each serosurvey, capillary blood samples were collected from
all participants on Whatman 3 filter paper. DAT was performed in
the laboratories of Banaras Hindu University (BHU -Varanasi) for
India, and in BPKIHS for Nepal, using a freeze-dried version of
DAT antigen composed of fixed, trypsin-treated and stained
promastigotes of L.donovani prepared in ITM-A [27]. Ten per cent
of the samples were repeated in the partner laboratory for quality
control. DAT was conducted as described by Harith et al. [28].
Briefly, disks of 5 mm diameter containing 50 ml of blood were
punched out of the filter paper and eluted overnight in a 1000 ml
tube at 4uC in Phosphate Buffered Saline (PBS – 7.2)
supplemented with protein, to obtain a starting dilution of
1:400. Serial dilution of the eluate in 0.9% saline, 1% foetal
bovine serum and 0.24 ml 2-mercaptoethanol were made in V-
shaped well microtiter plates, giving a range from 1:400 up to
1:25600. Results were read visually against a white background
after 18 h.
e. Data analysis
In order to allow comparison of our results with publications
from other VL endemic areas we calculated the relation between
infection and disease in two ways: 1) as a ratio of number of
incident infections to incident VL cases in a given time period, and
2) as a rate ratio.
The ratio of infection to clinical disease was calculated
comparing the number of asymptomatic seroconversions with
the number of incident VL cases in a given period.
The ratio of the infection rates was calculated using the
incidence rates of infection (seroconversion) and clinical VL over
the available time period of observation (2 years for incident
infection, two and a half years for incident VL).
Risk of progressing to clinical VL in recently infected
asymptomatic persons was calculated by comparing the cumula-
tive incidence of VL in the one and a half year of follow-up in the
cohort of seroconverters of year 1, with the cumulative incidence
of VL in those who had not seroconverted in the same year 1.
We also calculated two other incidence rates of interest: i) the
incidence rate of VL over the 2.5 years in the full population
(instead of the cohort with full serological data only), and ii) the
incidence rate of VL in year 1 in those who were DAT-positive at
baseline.
Confidence intervals were calculated using 95% CI formula for
rates, and Pearson’s x2 for CI on rate ratios.
The Kalanet study was funded by the European Commission
(contract No INCO-CT 2005-01537, Kalanet project). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Results
The total study population was 21,267 of which 49.1% were
women; 17.0% were under five years of age, 42.6% under fifteen.
Details on the study populations in India and Nepal are provided
elsewhere [21–23]. In brief, individual (i.e. age and gender
distribution) and socio-economic characteristics were similar in
both countries. The main difference was that the prevalence of
DAT-positive results in those with no VL history at baseline was
almost twice as high in India as it was in Nepal (18 vs 9%). In the
study population with no VL-history (N= 20071) and regardless
of serostatus, 120 new VL cases were diagnosed during the study
(VL relapses excluded), or an overall incidence rate of VL of 2.4/
1000 PY (95% CI 1.9–2.9). 1,196 had had VL in the past and
90.6% of them were DAT positive. From those without prior VL
Author Summary
Visceral Leishmaniasis is well known as a public health
problem in North-Indian Bihar state and adjacent districts
in Nepal, with about 300.000 new cases per year. As not
all infections with L.donovani lead to disease, the impact
of control programs should not only be measured in
numbers of VL cases, but also in number of new
infections. So far there have been little or no data on
the infection:disease ratio for this region, and the
evolution of these latent infections. Using DAT serocon-
version as a marker of infection, we found incident
asymptomatic infection to be nine times more frequent
than incident VL disease in high-endemic villages in India
and Nepal, and about 1 in 50 of these latent infections
lead to VL in the next 18 months, while over 80% turn
seronegative again within a year. Asymptomatic DAT-
positivity detected through screening in a person with no
history of VL, and especially in case of documented recent
seroconversion, is a risk factor for ultimately developing
VL. Further studies on transient and persistent asymp-
tomatic L. donovani infection are needed to better
understand their immunological patterns and seroki-
netics, their level of infectivity, and their potential for
later progression to VL.
L. donovani Latent Infection versus VL Disease
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and who provided a sample at baseline, 1,159 (9.25%) were
DAT-positive and 11,374 (90.75%) were DAT-negative. A cohort
of 9,034 baseline DAT-negative individuals with full clinical and
serological dataset was retained for the infection:disease ratio
analysis, and for the calculation of the incidence rate of
seroconversion. Participants’ flow (exclusion/inclusion) is sum-
marized in Figure 1.
Clinical and serological outcomes of the 9034 DAT-negative
persons at baseline are detailed in Figure 2. Sixty three persons
developed VL in the course of the study, 42 in the first year (Nov
2006 to Oct 2007), 19 in the second (Nov 2007 to Oct 2008) and 2
in the six months of follow up after the last serosurvey (Nov 2008
to May 2009) giving an average incidence rate of 2.8/1000 person
years (PY) (95% CI: 2.1–3.5). Of the 61 VL cases occurring before
the final serosurvey (Nov 2008), 59 had a documented serocon-
version while 2 remained DAT-negative. These 2 cases were
young children (5 and 6 years old) suffering from malnutrition.
Both cases had a RDT positive test at the time of diagnosis but
DAT-negative results at the serosurveys that preceded and
followed their VL episode.
Figure 1. Flowchart of selection process for study population. Population that was followed up during the Kalanet study covered 21,267
individuals in 26 highly endemic villages in India and Nepal. For the current analysis, only individuals who 1) had no history of Visceral Leishmaniasis
2) were seronegative at baseline (DAT-) and 3) had complete clinical and serological data from baseline to end of the study period= 30 months.
DAT=Direct Agglutination Test, cut-off used for positivity was titer $1:1600.
doi:10.1371/journal.pntd.0001284.g001
L. donovani Latent Infection versus VL Disease
www.plosntds.org 3 October 2011 | Volume 5 | Issue 10 | e1284
All calculations of incidence rates, per year, for disease and
infection are shown in Table 1. Results per country are provided
in Table S1.
In the first year, 42 individuals in the cohort developed VL, 375
showed an asymptomatic seroconversion and 8617 kept their
seronegative status. The infection:disease ratio was thus 8.9 to 1
(Table 1).
In the follow-up period (18 months), 7 of the 375 latently
infected individuals developed VL, giving an incidence rate of
12.44/1000 PY (95% CI: 3.25–21.80) in this group. In the 8617
with no seroconversion or VL recorded in the first year, 14 new
VL cases occurred in the follow-up period, giving an incidence
rate of 1.1/1000 person years (95% CI: 0.23–1.94). By the time of
the third serosurvey (November–December 2008), 85% (318) of
the asymptomatic seroconverters had turned seronegative again.
In year 2 (12 months’ period) the infection:disease ratio was 130
asymptomatic seroconverters against 12 new VL cases, or 10.8:1.
The subsequent follow-up period (6 months) was too short to
calculate VL incidences in this group of seroconverters.
Incidence rate of DAT seroconversion was 46.0 per 1000
person-years (PY) in the first year (95% CI: 41.6–50.5) and 16.4
per 1000 PY in the second (95% CI 13.7–19.1). Over the two
years, the average infection incidence rate was 31.6/1000 PY
(95% CI 28.9–34.2).
Incidence rate of VL was 4.6/1000 PY in the first year (95% CI
3.2–6.1) and 2.1/1000 PY in the second (95% CI 1.2–3.1). The
average incidence rate of VL over 30 months in this cohort of
9034 was 2.8/1000 PY (95% CI, 2.1–3.5). The ratio between the
incidence rates of infection and disease in the cohort was thus 11.3
to 1 (31.6 divided by 2.8).
Recent seroconversion was a strong risk factor for the
development of VL in these high endemic villages. Incidence of
VL in year 2 in persons with recent seroconversion was 11.5 times
higher than in the rest of the village population (12.4 vs 1.1/1000
PY=4.66,RR,28.30).
Incidence of VL in year 1 in those who were already DAT
positive at baseline (data not shown here) was 15.9/1000 PY (95%
CI 8.5–23.2), more than 3 times the 4.6/1000 PY incidence rate
found in year 1 in individuals with negative DAT at baseline
(Relative risk 3.42 (1.97,RR,5.92; p,0.0001)).
Discussion
Prospective epidemiological population-based studies on inci-
dence of L. donovani infection and VL disease are scarce. This is the
first study done in India and Nepal providing data on
infection:disease ratio and on the risk for development of VL in
recently infected individuals.
In our study, the ratio of numbers of infection to disease was
about 9 (8.9 for the first year, 8.0 over the whole study period) and
the rate ratio about 10 (9.9 for year 1 and 11.3 for the full length of
the study). Because of the relatively low number of VL cases,
calculations per country per year give a wider variation.
Nevertheless, incidence rates of infection and disease in India
Figure 2. Flowchart of clinical and serological events in study population. Bars in light grey: Results of the 3 serosurveys IS1 (Immunosurvey
1), IS2 and IS3 that took place in November–December of 2006, 2007 and 2008 respectively. In between the bars: clinical events occurring in between
the serosurveys, or in the 6 months following the last serosurvey.
doi:10.1371/journal.pntd.0001284.g002
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are generally twice as high as in Nepal, and in both countries rates
decreased in the second year (Table 1). The ratio infection:disease
was 7.6 for India and 9.6 for Nepal, and rate ratios were 10.8 and
13.2 respectively.
The ratio of infection to disease may differ from one village to
another and also fluctuates over time within the same population,
as reported earlier by Khalil et al. [29]. The determinants of this
ratio include age, genetics, nutritional status and concomitant
disease, all features that can be clustered in villages or parts of
villages. The most important determinant appears to be living in
proximity to a previous VL patient, as shown in a recent review by
Bern et al. [30]. The closer to a VL case, the higher is the
probability of infection becoming symptomatic.
Similar studies have been conducted in VL-endemic areas in
Brazil, Ethiopia, Kenya, Sudan and Bangladesh, but methods
differ between studies (i.e. in terms of serological tests and case
definitions), and are sometimes not explicitly stated. Most studies
report the ratio of asymptomatic infection to disease. These ratios
range from 18.5:1 to 6.5 in Brazil (American VL occurring in
children below 15 and caused by L. infantum/chagasi) [13,15], and
from 11:1 to 1:2.4 in Africa [18,29]. In other prospective studies,
incidence rates of infection (seroconversion) and VL disease are
reported, allowing to calculate the Rate Ratio (RR): these rates
were respectively 46/1000 and 5.1/1000 PY (RR=9.0) in Brazil
[13], 9/1000 and 2.2/1000 PY (RR=4.1) in Baringo district,
Kenya [17] 106/1000 and 19.4/1000 PY (RR 5.5:1) in Ethiopia
[16] and 63.1/1000 and 15.6/1000 PY (RR=4:1) in Bangladesh
[20].
Our analyses were limited in different ways. In contrast with
the aforementioned studies, we only used one serological test
(DAT) and did not test for cellular immunity (LST). Studies on
asymptomatic L.donovani infection are hampered by the absence
of validated definitions and appropriate biological markers. The
pathway, starting from the initial infective sandfly bite up to
symptomatic visceralisation or asymptomatic infection is ex-
tremely complex, whereby different types of immunity (innate,
humoral, cellular) play their role in the process of clearing or
containing the progressive infection in skin, lymph node and
spleen [31] : It can be assumed that in a number of individuals
infection will be cleared rapidly by innate immunity, not resulting
in an over time measurable immune response, while in the other
extreme the infection may only be contained at the latest stage,
by (long-lasting) cell-mediated immunity after visceralisation. In
comparative studies of serologic tests for asymptomatic VL, the
different tests validated for confirmation of symptomatic VL
(DAT, immunofluorescence (IFAT), ELISA using promastigotes
as well as recombinant antigen, and LST) and comparison with
PCR methods show low agreement [32–34] suggesting that
different tests may indicate different time points and/or levels of
infection/immune responses), and that only a combination of
different tests can pick up all new infections. We chose DAT
because it is relatively cheap and easy to perform [28], and
because in comparison to LST, it requires only one visit and
seroconversion occurs early after infection. A positive LST result
is thought to indicate durable cell-mediated immunity after
asymptomatic infection or clinical cure of VL, but LST positivity
may only appear months to years after infection. A problem is
that in LST positives, transient humoral immune responses can
still be measured [35], be it as a sign of re-exposure, or a change
in the capacity of the host to control the latent infection. A
number of DAT seroconversions observed in our study may thus
be reactivations in individuals with already acquired cellular
immunity, and may not represent a risk to develop disease. In the
Bangladesh study, the LST prevalence was 33% [20]. Earlier
Table 1. Rate and ratio calculations per year.
Cases Denom. Rate/1000PY (95% CI))
Year 1 VL incidence year 1 42 9034 4.65 (3.24–6.06)
Seroconversion incidence during year 1 416 46.05 (41.62–50.47)
Asymptomatic seroconversion incidence 375 41.51 (37.31–45.71)
Year 2 VL incidence in 18 months of follow up 21 8986 1.56 (0.89–2.23)
- in seroconvertors of year 1 7 375 12.52 (3.25–21.80)
- in DAT-negatives 14 8570 1.08 (0.52–1.65)
VL incidence during year 2 (12months) 19 8992 2.11 (1.16–3.06)
Seroconversion incidence during year 2 141 8617 16.36 (13.66–19.06)
TOTAL VL incidence in 30 months of follow-up 63 22512,5 2.80 (2.11–3.49)
Seroconversion incidence 557 17651 31.56 (28.94–34.18)
Asymptomatic seroconversion incidence 505 17651 28.61 (26.11–31.11)
Ratio infection: disease:
- year 1 8.9 : 1
- year 2 10.8 : 1
- full study period 8.0 : 1
Rate ratio infection : disease:
- year 1 9.9 : 1
- year 2 11.7 : 1
- full study period 11.3 : 1
Definitions: Asymptomatic seroconversion: Seroconversion in DAT titer compared to previous year’s DAT result, without clinical signs of VL at the time of the DAT-positive
blood sampling.
doi:10.1371/journal.pntd.0001284.t001
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studies in high-endemic foci in India and Nepal give prevalence
figures of 19% and 13.2% [5,36] respectively. In the preparation
phase of the KALANET study, LST performance was evaluated
(L. major antigen, Pasteur Institute, Iran) but gave unreliable
results [37] and was therefore abandoned.
The incidence of infection was measured by yearly serological
testing. In the observed seroconverters who remained asymptom-
atic, we found that seropositivity did not last into the second year
in 86.7%. This is in line with what is reported elsewhere [7,13,17].
Six-monthly serological testing might therefore have detected
more seroconversions, which would have led to a higher ratio.
In the 375 DAT-seroconverters that were asymptomatic at the
time of serodiagnosis, 7 developed VL (almost 1 in 50), showing an
increased risk compared to non-seroconverters. Recent serocon-
version in DAT must therefore be considered as a risk factor for
VL. In a prospective study done in 2005–07 in a single community
of Muzaffarpur district, Bihar State, India [9], no statistical
difference in VL incidence had been observed between those
DAT-positive and -negative at baseline in the 2 years following the
survey, but serostatus was only tested once (at baseline) giving no
data on recent seroconversion. In other, smaller studies, DAT
positivity was a strong predictor of developing VL but these studies
were done in asymptomatic household contacts of active VL and
PKDL patients [38,39] where VL incidence is known to be high
[40]. In a recent study in Bihar by Topno et al. [41] 18.42% of the
38 healthy individuals who tested positive to either DAT, rK39
strip test or PCR developed clinical VL in less than 6 months. The
rate of progression to disease reported was 17.85/1000 PY which
is similar to the one we obtained in DAT positive individuals at
baseline (15.9/1000 PY). In contrast to our study, the Topno et al.
study was based on a small cohort (n = 335) from a single village
and asymptomatic cases, identified in a single cross-sectional
survey, were followed for a maximum of 12 months.
For those ultimately evolving to clinical VL, DAT may become
positive some months before clinical symptoms appear [42]. By
timing our yearly serosurveys in November and December, which
is shortly after the pre-winter peak of sandfly density [43], we may
have picked up more pre-clinical VL cases than other studies.
Incubation period for full-blown visceral leishmaniasis is typically
3–8 months [19]. Prospective studies, including ours, show disease
conversion in DAT-positive individuals taking place at any time,
mostly within 6 months [7] but also up to two years after the
baseline survey [9]. Analysis of all incident VL cases in our study
has shown that 35% of them were already DAT-positive in the
serosurvey that pre-ceded the year of developing VL (data not
reported here). From those who developed VL in the 2nd and 3rd
year of the study and had baseline DAT results (resp. 27 and 5),
20% were already seropositive at baseline.
PCR-detection of the parasites could have been an alternative
method to estimate the infection rates. In a recent study done on a
subgroup of the study population [44], we found similar positivity
rates between PCR and DAT (respectively 18 and 16.1%), but a
poor agreement between the two methods. This highlighted the
specific character of both methods to explore asymptomatic
infections, (i) PCR being probably more informative to detect very
recent infections, before any immune response has controlled the
infection, (ii) while DAT provides a later picture of the infections.
Follow-up studies are needed to further precise the dynamics of the
infection markers revealed by both methods (including the return
to negative status over time) but in the meantime, DAT appears
more adequate, especially for high-throughput applications.
There was a sharp decline in the incidence of VL in year 2
compared to year 1. Several explanations can be put forward: VL
occurs in localized epidemics so when villages were selected on the
basis of VL incidence, they were likely to be at their peak
incidence after which incidences were likely to decrease. One may
also hypothesize that the active and systematic screening for
suspected cases and subsequent treatment may have had an
impact on transmission. On the other hand, a decline in VL
incidence has been observed in the national records of Nepal and
India over recent years, expressing possibly the result of increased
control efforts, alongside other factors such as climate changes
influencing sandfly density.
Conclusion
Using DAT seroconversion as a marker of infection, we found
incident asymptomatic infection to be eight times more frequent
than incident VL disease in India and Nepal, and about 1 in 50 of
these latent infections lead to VL in the next 18 months.
Asymptomatic DAT-positivity detected through screening in a
person with no history of VL, and especially in case of documented
recent seroconversion, is a risk factor for ultimately developing
VL. Further studies on latent infection are needed to better
understand the serokinetics, and possibly identify markers for
progression to VL. Such studies should ideally combine DTH
tests, PCR and different serological tests to measure levels and
timing of humoral and cellular response after exposure.
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